Article info
PDFORIGINAL ARTICLE
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
- Address correspondence and reprint requests to: Richard T. Penson, M.R.C.P., M.D., Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Yawkey 9066, 55 Fruit Street, Boston, Massachusetts 02114-2617. Email: rpenson{at}partners.org
Citation
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
Publication history
- First published August 1, 2008.
Online issue publication
March 06, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2008 Blackwell Publishing Ltd.